CHEMM ChemoMetec

Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year

Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year

ANNOUNCEMENT NO. 261



Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year

According to the preliminary figures, revenue in the third quarter of 2023/24 was DKK 98.9 million and in the first nine months of 2023/24 DKK 298.2 million.

Based on the development in the third quarter of 2023/24 and the expectations for the remaining part of the financial year, expectations for revenue for the 2023/24 financial year are clarified. Hence, revenue in 2023/24 is expected to be in the DKK 400-415 million range against previously announced DKK 400-435 million and thus still within the most recently announced range.

Earnings in the third quarter of 2023/24 have been affected by one-off costs in connection with organizational changes, and, among other things, as a result of this, an operating result (EBITDA) of DKK 185-200 million is expected in 2023/24 against previously announced DKK 200-220 million.

Final figures for the third quarter 2023/24 and for the first nine months of 2023/24 will be included in the interim report for the third quarter 2023/24, which will be published on 8 May 2024.



For further information

Niels Høy Nielsen, CFO

Phone: (+45) 2551 8724



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to





Attachment



EN
12/04/2024

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 301                 9. februar 2026 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af bestyrelsesformand Niels Thestrups transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20      ...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 301 9 February 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10...

February 9, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec enters Letter of Intent with Roche Diagnostics ANNOUNCEMENT NO. 300 – IN ENGLISH ONLY 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing a co...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec enters Letter of Intent with Roche Diagnostics ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing a connectivity of Chem...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

1. halvår 2025/26 - Organisk vækst trods udfordringer på det nordameri...

1. halvår 2025/26 - Organisk vækst trods udfordringer på det nordamerikanske marked MEDDELELSE NR. 299 4. februar 2026 Delårsrapport for første halvår 2025/26 Organisk vækst trods udfordringer på det nordamerikanske marked Martin Helbo Behrens, CEO: I 1. halvår steg vores omsætning målt i lokale valutaer med 3%, mens den i danske kroner var på DKK 249,0 mio., svarende til et fald på 1% i forhold til samme periode sidste år. Trods dette viste driftsresultatet (EBITDA) og EBITDA-marginen en mindre stigning. Omsætningen var påvirket af en brat opbremsning i efterspørgslen i USA. Det skyl...

February 4, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch